Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus

American Journal of Cardiovascular Drugs

Volumn 3, Issue 5, 2003, Pages 315-320

  Menè, Paolo ^a,b   Festuccia, Francescaromana ^a   Pugliese, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 3 PHENACETYL 4,5 DIMETHYLTHIAZOLIUM CHLORIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANTIDIABETIC AGENT; CARNOSINE; EXO 226; GELATINASE A; GELATINASE B; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; ISOBUTYRIC ACID DERIVATIVE; LIPID; LYSOZYME; METFORMIN; METHYLGUANIDINE; MONOCLONAL ANTIBODY; N [2 (N AMINOGUANIDINO)ETHYL]ACETAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PYRIDOXAMINE; STROMELYSIN; SULFONYLUREA; TENILSETAM; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; BLOOD VESSEL INJURY; CLINICAL STUDY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION; VASCULAR DISEASE;

CLINICAL TRIALS; DIABETES MELLITUS; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS;

EID: 0242551521     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303050-00002     Document Type: Review

References (69)

1. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 1991; 266: 11654-60
2. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 1991: 325: 836-42
3. Monnier VM, Nagaraj RH, Portero-Otin M, et al. Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant 1996; 11 Suppl. 5: 20-6
4. Porte Jr D, Schwartz MW. Diabetic complications: why is glucose potentially toxic? Science 1996; 272: 699-700
5. Onorato JM, Jenkins AJ, Thorpe SR, et al. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine. J Biol Chem 2000; 275: 21177-84
6. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-50
7. El Khoury J, Thomas C, Loike J, et al. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994: 269: 10197-200
8. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45 Suppl. 3: S77-80
9. Makino H, Shikata K, Hironaka K, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995: 48: 517-26
10. Schmidt AM, Hofmann M, Taguchi A, et al. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000; 26: 485-93
11. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997; 94: 6474-9
12. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation endproducts: a nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-80
13. Yanagisawa K, Makita Z, Shiroshita K, et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 1998: 47: 1348-53
14. Floridi A, Antolini F, Galli F, et al. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17: 871-8
15. Sakata N, Imanaga Y, Meng J, et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999; 142: 67-77
16. Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Res Clin Pract 1996; 30S: 123-30
17. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999; 48: 2446-53
18. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97
19. Stitt AW, He C, Vlassara H. Characterization of the advanced glycation endproduct receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 1999: 256: 549-56
20. Pugliese G, Pricci F, Iacobini C, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 2001; 15: 2471-9
21. Ohgami N, Nagai R, Ikemoto M, et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2001; 947: 350-5
22. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-24
23. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001: 159: 399-403
24. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-31
25. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-24
26. Huang JS, Guh JY, Hung WC, et al. Role of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem J 1999; 342: 231-8
27. Malherbe P, Richards JG, Gaillard H, et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999; 71: 159-70
28. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras) dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-4
29. Sugimoto H, Shikata K, Wada J, et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-86
30. Skolnik EY, Yang Z, Makita Z, et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174: 931-9
31. Crowley ST, Brownlee M, Edelstein D, et al. Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes 1991; 40: 540-7
32. Ziyadeh FN, Han DC, Cohen JA, et al. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-β system. Kidney Int 1998; 53: 631-8
33. Menè P, Pascale C. Bernardini S, et al. Effects of advanced glycation endproducts on [Ca2+]i signalling of cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 1478-86
34. Ivanov GI, Chaushev TA, Dakovska LN, et al. Increased adhesion of lymphoid cells to glycated proteins. Int J Biochem Cell Biol 1999; 31: 797-804
35. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999: 10: 822-32
36. Youssef S, Nguyen DT, Soulis T, et al. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 1999; 55: 907-16
37. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97
38. Loske C, Neumann A, Cunningham AM, et al. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm 1998; 105: 1005-15
39. Price DL, Rhett PM, Thorpe SR, et al. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 270: 48967-72
40. Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002: 11: 565-74
41. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arteriole wall protein cross-linking. Science 1986; 232: 1629-32
42. Picard S, Parthasarathy S, Fruebis J, et al. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc Natl Acad Sci U S A 1992; 89: 6876-80
43. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50: 1636-42
44. Kelly DJ, Gilbert RE, Cox AJ, et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-107
45. Sugimoto H, Shikata K, Wada J, et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-86
46. Brown CD, Zhao ZH, Thomas LL, et al. Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. Am J Kidney Dis 2001: 38: 1414-20
47. Ziolo MT, Katoh H, Bers DM. Expression of inducible nitric oxide synthase depresses beta-adrenergic-stimulated calcium release from the sarcoplasmic reticulum in intact ventricular myocytes. Circulation 2001; 104: 2961-6
48. Whittier F, Spinowitz B, Wuerth JP, et al. Pimagidine (PG) safety profile in patients with type 1 diabetes mellitus (DM). J Am Soc Nephrol 1999; 10: 184A
49. Freedman BJ, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). Control Clin Trials 1999: 20: 493
50. Viberti GC, Slama G, Pozza G, et al. Early closure of European Pimagedine Trial. Lancet 1997; 350: 214-5
51. Rahbar S, Yernini KK, Scott S, et al. Novel inhibitors of advanced glycation endproducts. Biochem Biophys Res Commun 1999; 262: 651-6
52. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999; 257: 251-8
53. Bonnefont-Rousselot D. Antioxidant and anti-AGE therapeutics: evaluation and perspectives. J Soc Biol 2001; 195: 391-8
54. Rabbar S, Natarajan R, Yemeni K, et al. Evidence that pioglitazone, metformin and pentoxyfilline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65
55. Miyata T, Ueda Y, Asahi K, et al. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 2000; 11: 1719-25
56. Miyata T, Ueda Y, Yamada Y, et al. Accumulation of carbonyl stress accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress uin uremia. J Am Soc Nephrol 1998; 9: 2349-56
57. Wada R, Nishizawa Y, Yagihashi N, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-20
58. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-88
59. Seidler NW, Yeargans GS. Effects of thermal denaturation on protein glycation. Life Sci 2002; 70: 1789-99
60. Cohen MP, Masson N, Hud E, et al. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp Nephrol 2000; 8: 135-43
61. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001: 10: 1977-87
62. Asif M, Egan J, Vasan S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000, 97: 2809-13
63. Vaitkevicius PV, Lane M, Spurgeon H, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001; 98: 1171-5
64. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-70
65. Lyford J. Selected highlights from the 50th Annual Scientfic Session of the American College of Cardiology, Orlando USA March 2001, 18-21. Curr Control Trials Cardiovasc Med 2001 March; 2: 85-9
66. Alteon's hypertension drug fails to achieve main gaol in Phase IIb trials. Pharma Marketletter 2003 Jul 28; 19
67. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-14
68. Cohen MP, Sharma K, Jin Y, et al. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: a novel treatment strategy. J Clin Invest 1995; 95: 2338-45
69. Zheng F, Cai W, Mitsuhashi T, et al. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy? Mol Med 2001; 7: 737-47